- Afdhal, NH. and Nunes, D. 2004. Evaluation of liver fibrosis: a concise review. Am J Gastro- enterol.; 99(6):1160–1174.
- Anttonen A, Leppä S, Ruotsalainen T, Alfthan H, Mattson K, Joensuu H. 2003. Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 41:171–7.
- Bedossa, P. and Poynard, T. 1996. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 24 (2):289–93.
- Bedossa, P., Dargere, D. and Paradis V. 2003. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology, 38(6): 1449–1457
- Bedossa, P., Poynard T., Abella A., Paraf F., Lemaigre, G and Martin, ED. 1989. Localization of apolipoprotein A-I and apolipoprotein A-II in normal and atherosclerotic arteries. Arch Pathol Lab Med., 113:777-780.
- Calès P1., Oberti F., Michalak S., Hubert-Fouchard I., Rousselet MC., Konaté A., Gallois Y., Ternisien C., Chevailler A. and Lunel F. 2005. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology, 42:1373-1381.
- Chen SL. and Morgan TR. 2006. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci., 3 : 47-52. Dudas J., Kovalszky I., Gallai M., Nagy J.O, Schaff Z., Knittel T., Mehde M., Neubauer K., Szalay F. and Ramadori G.
- 2001. Expression of decorin, transforming growth factor- beta 1, tissue inhibitor metalloproteinase 1 and 2, and type IV collagenases in chronic hepatitis, Am J Clin Pathol., 115, 725–735.
- Forns X., Ampurdanès S., Llovet JM., Aponte J., Quintó L., Martínez-Bauer E., Bruguera M., Sánchez- Tapias JM. and Rodés J. 2002. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology, 36:986-992.
- Friedman LS. 2004. Controversies in liver biopsy: who, where, when, how, why? Curr Gastroenterol Rep., 6(1): 30–36.
- Friedman SL. 2008. Mechanism of hepatic fibrogenesis.
- Gastroenterology, 134:1655–69.
- Gangadharan B., Antrobus R., Dwek RA. and Zitzmann N 2007. Novel Serum Biomarker Candidates for Liver Fibrosis in Hepatitis C Patients. Clinical Chemistry, 53:1792–1799.
- Gressner A.M., Krull N. and. Bachem M.G. 1994. Regulation of proteoglycan expression in fibrotic liver and cultured fat-storing cells. Pathol Res Pract., 190, 864–882
- Gressner AM. 1998. The cell biology of liver fibrogenesis an imbalance of proliferation growth arrest and apoptosis of myofibroblasts. Cell Tissue Res., 292:447-52.
- Heinegard D. and Oldberg A. 1989. Structure and biology of cartilage and bone matrix noncollagenous macromolecules, FASEB J3, 2042–2051.
- Hogemann B., Edel G., Schwarz K., Krech R. and Kresse H. 1997. Expression of biglycan, decorin and proteoglycan- 100/CSF-1 in normal and fibrotic human liver, Pathol Res Pract193, 747–751.
- Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y. and Poynard T. 2001. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet, 357:1069-1075.
- Jarnagin W.R., Rockey D.C., Koteliansky V.E., Wang S.S and. Bissell D.M. 1994. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis, J Cell Biol., 127 :2037–2048.
- Kainulainen V., Wang H., Schick C. and Bernfield M. 1998. Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J Biol Chem., 273: 11563–9.
- Kim CW., Goldberger OA., Gallo RL. and Bernfield, M. 1994. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue- and development-specific patterns. Mol Biol Cell., 5: 797–805.
- Kim TH., Lee YH., Kim KH., Lee SH., Cha JY., Shin EK., Jung S., Jang AS., Park SW., Uh ST., Kim YH., Park JS., Sin HG., Youm W., Koh ES., Cho SY., Paik YK., Rhim TY. and Park CS. 2010. Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am J Respir Crit Care Med., 182: 633–642.
- Le Calvez S., Thabut D., Messous D., Munteanu M., Ratziu V., Imbert-Bismut F. and Poynard, T. 2004. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C., Hepatol; 39:862-3.
- Lee EH., Lee EJ., Kim HJ., Jang AS., Koh ES., Kim Y., Park,
- S. and Park, C. 2013. Overexpression of Apolipoprotein A1 in the Lung Abrogates Fibrosis in Experimental Silicosis. PLoS ONE 8(2): e55827.
- Li Q., Park PW., Wilson CL. and Parks WC. 2002. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell, 111:635.
- Martı´nez S M., Crespo G., Navasa M. and Forns X. 2011. Noninvasive Assessment of Liver Fibrosis: Hepatology, 53:325-335
- Martinez-Hernandez and Amenta P.S. 1993. The hepatic extracellular matrix. I. Components and distribution in normal liver, Virchows Arch A Pathol Anat Histopatho. l423, 1–11.
- Miller GJ. 1980. High density lipoproteins and atherosclerosis.
- Annu Rev Med., 31:97-108.
- Myers RP., Benhamou Y., Imbert-Bismut F., Thibault V., Bochet M., Charlotte F., Ratziu V., Bricaire F., Katlama C. and Poynard T. 2003. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS; 17:721–5.
- Naveau S., Poynard T., Benattar C., Bedossa P. and Chaput JC. 1994. Alpha-2-macroglobulin and hepatic fibrosis: diagnostic interest. Dig Dis Sci., 1994; 39:2426–32.
- Paradis V1., Laurent A., Mathurin P., Poynard T., Vidaud D., Vidaud M. and Bedossa P. 1996. Role of liver extracellular matrix in transcriptional and post-transcriptional regulation of apolipoprotein A-I by hepatocytes. Cell Mol Biol., 42:525–34.
- Parkes J., Guha IN., Roderick P. and Rosenberg W. 2006. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol., 44(3):462–474.
- Parsian H., Alizadeh M. and Negahdar H. 2012. Would the Physicians Eventually Obsolete the Liver Biopsy for the Assessment of Liver Fibrosis? Hepat Mon., 12(5): 353-4. DOI: 10.5812/hepatmon.6227.
- Pichard A.V., Mallet V., Nalpas B., Verkarre V., Nalpas A., Venier VD., Fontaine H. and Pol S. 2007. FIB-4: an Inexpensive and Accurate Marker of Fibrosis in HCV Infection. Comparison with Liver Biopsy and FibroTest. HEPATOLOGY, 46, (1), 32-36.
- Poynard T., Abella A., Pignon JP., Naveau S., Leluc R. and Chaput, JC. 1987. Apolipoprotein A-I and alcoholic liver disease. HEPATOLOGY;6:1391-1395.
- Poynard T., Aubert A., Bedossa P., Abella A., Naveau S., Paraf F. and Chaput JC. 1991. A simple biological index for detection of alcoholic liver disease in drinkers. Gastroenterology; 100:1397–402.
- Regev A., Berho M., Jeffers LJ., Milikowski C., Molina EG., Pyrsopoulos NT., Feng ZZ., Reddy KR. and Schiff ER. 2002. Sampling error and interobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol., 97: 2614-2618.
- Rosenberg WM1., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., Hubscher S., Roskams T., Pinzani M. and Arthur MJ. 2004. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology, 127:1704- 1713.
- Ryan KJ., Ray C.G. (editors), ed. 2004. Sherris Medical Microbiology (4th ed.). McGraw Hill. pp. 551–. ISBN 0838585299. 2- Rossi EG, Cardoso LF, Ávila WS, et al. Estenose Mitral em assintomáticos. Rev Soc Cardiol Estado de São Paulo 1997;7:741–746.
- Sabile A1, Perlemuter G., Bono F., Kohara K., Demaugre F., Kohara M., Matsuura Y., Miyamura T., Bréchot C. and Barba, G. 1999. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology; 30:1064–76.
- Seidel C., Sundan A., Hjorth M., Turesson I., Dahl IM., Abildgaard N., Waage A. and Borset M. 2000. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood;95: 388–92
- Shah AG., Lydecker A., Murray K., Tetri BN., Contos MJ. and Sanyal AJ. 2009. (Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. Oct; 7(10): 1104-12.
- Snyder N., Gajula L., Xiao SY., Grady J., Luxon B., Lau DT., Soloway R. and Petersen J. 2006. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis
- C. J Clin Gastroenterol., 40(6):535-42.
- Stepp MA., Liu Y., Pal-Ghosh S., Jurjus RA., Tadvalkar G., Sekaran A., Losicco K., Jiang L., Larsen M., Li L. and Yuspa SH. 2007. Reduced migration, altered matrix and enhanced TGFbeta1 signaling are signatures of mouse keratinocytes lacking Sdc1. J Cell Sci., 120:2851–2863.
- Sterling RK., Lissen E., Clumeck N., Sola R., Correa MC., Montaner J., S Sulkowski M., Torriani FJ., Dieterich DT., Thomas DL., Messinger D. and Nelson M. 2006. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 43(6):1317-1325.
- Subramanian SV., Fitzgerald ML. and Bernfield M. 1997. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem., 272: 14713–20.
- Teare JP., Sherman D., Greenfield SM., Simpson J., Bray G., Catterall AP., Murray-Lyon IM., Peters TJ., Williams
- R. and Thompson RP. 1993. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet; 342:895–98.Thampanitchawong P. and Piratvisuth T 1999. Liver biopsy:complications and risk factors. World J Gastroenterol, 5:301-304.
- Thomas DL1, Astemborski J., Rai RM., Anania FA., Schaeffer M., Galai N., Nolt K., Nelson KE., Strathdee SA., Johnson L., Laeyendecker O., Boitnott J., Wilson LE. and Vlahov
- D. 2000. The natural history of hepatitis C virus infection: host, viral, and environmental factors. Jama 284: 450–456.
- Vozar I. 2005. Serum laboratory markers for non invasive diagnosis and monitoring of liver fibrogenesis in patients with chronic liver diseases. Bratisl Lek Listy;106(3) :123- 6.
- Wai CT1, Greenson JK., Fontana RJ., Kalbfleisch JD., Marrero JA., Conjeevaram HS. and Lok AS. 2003. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 38: 518-26.
- World Health Organisation 2012, mediacentre/factsheets/ fs164/en/. Available : http://www.who.int/ May 23.
- Yang H R., Kim H R., Kim M J., Ko J S. and Seo J K. 2012. Noninvasive Parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastro‐enteric, l7; 18(13): 1525–30.
- Zannis VI., Kypreos KE., Chroni A., Kardassis D, Zanni EE. 2004. Lipoproteins and atherogenesis. In: Molecular Mechanisms of Atherosclerosis.Loscalzo J (ed). Taylor & Francis, New York, NY, pp. 111–74.
|